Asia Pacific Vaccine Market Report and Forecast 2024-2032

Asia Pacific Vaccine Market Size

The Asia Pacific vaccine market was valued at USD 4.56 billion in 2023, driven by the growing incidence of infectious diseases, rising innovations in vaccine technology, and increasing immunization programs in the region. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 7.8% to reach nearly USD 8.95 billion by 2032. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Asia Pacific Vaccine Market Outlook

• The rising incidence of infectious diseases and the growing public awareness regarding the benefits of vaccination impacts the market demand significantly.

• One of the major market trends is the increased focus on indigenous production of vaccines in the Asia Pacific region to facilitate a more reliable and stable supply of vaccines and reduce dependence on imported vaccines.

• The market share is influenced by the rising economic development, increased national immunization programs, and the surge in the launch of advanced vaccines.

Asia Pacific Vaccine Market Overview

A vaccine provides immunity against various contagious diseases. It stimulates the production of antibodies to boost the immune system and prevent the risk or severity of symptoms. It is a crucial preventive and affordable medicine that eliminates the risk of hospitalization or prolonged illness from various diseases, such as hepatitis, influenzas, and Japanese Encephalitis, among others.

The Asia Pacific vaccine market is characterized by the increasing prevalence of infectious disease outbreaks, especially in developing regions, such as India, Indonesia, and Thailand, among others, that surges the demand for efficient vaccines. The growing economic development in countries like China and India is leading to increased healthcare spending, which also impacts the global vaccine market. Moreover, governments are increasingly boosting vaccine purchase to ensure free vaccination of children to boost the overall quality of life of their citizens. For example, in August 2019, the Indian government announced the expansion of coverage of the rotavirus vaccine to end fatality and morbidity associated with the virus by 2023. Other factors that shape the market dynamics include heightened public awareness about the benefits of vaccination, strategic partnerships, and rising advancements in vaccine production technologies.

Asia Pacific Vaccine Market Growth Drivers

Increased Focus on Indigenous Production of Vaccines to Affect the Market Landscape Significantly

In January 2024, Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board and a leading human vaccine manufacturer in India, launched its vaccine Havisure, the first indigenously developed Hepatitis A vaccine, in Hyderabad (India). Havisure is a two-dose vaccine, with the first dose recommended for children above 12 months of age, and the second dose is administered at least 6 months after the first dose. The vaccine is reported to show comparable efficacy and safety as the international standards of Hepatitis A vaccine and has undergone rigorous clinical trials in 8 centers. This surge in the launch of indigenous vaccines is a significant growth driver of the market and is likely to improve self-reliance, affordability, and access to vaccines in the Asia Pacific region.

Increasing Availability of Vaccines to Meet Rising Asia Pacific Vaccine Market Demand

The robust growth of the healthcare sector in the region is propelling the market growth. The emergence of various start-ups and international companies in countries such as China and India is escalating the availability of critical vaccines, boosting the market share. In addition, the rising affordability and quality of vaccines owing to extensive indigenous manufacturing are significantly contributing to the growth of the market. The initiation of vaccination drives and campaigns by non-profit and humanitarian organizations is further increasing the accessibility and demand for vaccines in the region.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Asia Pacific Vaccine Market Trends

The market is witnessing several trends and developments to improve the current scenario in the Asia Pacific. Some of the notable trends are as follows:

Asia Pacific Vaccine Market Segmentation

Market Breakup by Composition

• Combination Vaccine

• Mono Vaccine

Market Breakup by Type
 

• Recombinant and Conjugate Vaccine

• Inactivated Vaccines

• Live Attenuated Vaccines

• Toxoid Vaccines

• Others

Market Breakup by Age

• Pediatric

• Geriatric

• Adult

Market Breakup by Indication

• Pneumococcal Disease

• Influenza

• Typhoid

• Rabies

• Yellow Fever

• Human Papilloma Virus (HPV)

• Meningococcal Disease

• Varicella, Measles, Mumps, and Rubella

• Diphtheria, Pertussis, and Tetanus (DPT)

• Polio

• Hepatitis

• JE (Japanese Encephalitis)

• Others

Market Breakup by Route of Administration

• Injectable

• Oral

• Nasal

Market Breakup by Country

• China

• Japan

• India

• ASEAN

• Australia

• Others

Asia Pacific Vaccine Market Share

Market Segmentation Based on Type is Anticipated to Witness Substantial Growth

The market segmentation based on the vaccine type includes recombinant and conjugate vaccines, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. The recombinant and conjugate vaccines segment represents a considerable share of the market due to their high efficacy and safety and their increased adoption in national immunization programs to prevent common and serious infections such as hepatitis B and meningococcal disease. On the other hand, inactivated vaccines are widely used for immunocompromised individuals due to their strong safety profile.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Asia Pacific Vaccine Market Analysis by Region

Based on the region, the market is segmented into China, Japan, India, ASEAN, and Australia, among others. In China, the market is poised to witness significant growth owing to increasing research and development (R&D) activities in the region. Moreover, the extensive production of vaccines, along with the presence of several leading companies is bolstering the market value. The introduction of various government initiatives to enhance capabilities in the biotechnology sector is augmenting the market growth. Furthermore, leading companies are increasingly investing in the country for the development of novel vaccines owing to the availability of cost-effective raw materials and highly skilled laborers, which is providing further impetus to the growth of the market.

Leading Players in the Asia Pacific Vaccine Market

The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the key players. The major companies in the market are as follows:

CSL

This global biotechnology company, Commonwealth Serum Laboratories (CSL) Limited, is headquartered in Melbourne, Australia, and is popular for its influenza and COVID-19 vaccines. CSL boasts robust R&D capabilities and an extensive distribution network in the Asia Pacific region.

Bharat Biotech International Limited

Indian multinational biotechnology company Bharat Biotech International Limited stands as a leading manufacturer of high-quality vaccines and bio-therapeutics. It is known for developing Covaxin (COVID-19), Rotavac (rotavirus), and Typbar TCV (typhoid) vaccines, and significantly contributes to the Asia Pacific vaccine market share.

GSK plc

GSK plc (GlaxoSmithKline), a multinational pharmaceutical and biotechnology company, holds a strong portfolio that includes vaccines for diseases such as hepatitis, influenza, human papillomavirus (HPV), and meningitis, among others.

Pfizer Inc.

Pharmaceutical giant Pfizer Inc. has a prominent presence in the market due to its strong manufacturing capabilities and wide distribution network. Pfizer is known for its COVID-19 vaccine, Comirnaty, which it developed in collaboration with BioNTech.

Other key players in the market include AstraZeneca PLC, Biological E. Limited, Serum Institute of India, Takeda, Merck & Co., Inc., Abbott, and Sanofi.

Key Highlights of the Report

Key Questions Answered in the Asia Pacific Vaccine Market Report 

• What was the Asia Pacific vaccine market value in 2023?
• What is the Asia Pacific vaccine market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on the composition?
• What is the market breakup based on the type?
• What is the market breakup by age?
• What is market segmentation based on the indication?
• What are the different routes of administration available in the market?
• What are the major factors aiding the Asia Pacific vaccine market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of infectious diseases affect the market landscape?
• What are the major Asia Pacific vaccine market trends?
• How does the rising economic growth in the Asia Pacific region impact the market size?
• Which vaccine composition will dominate the market share in the Asia Pacific? 
• Which vaccine type is expected to have a high market value in the coming years?
• Which age group will cover the highest market share?
• Which indication will experience the highest demand in the market segment?
• Which route of administration is projected to contribute to the highest market growth?
• Who are the key players involved in the Asia Pacific vaccine market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?